Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
BioNTech SE - American Depositary Shares
(NQ:
BNTX
)
110.03
+1.77 (+1.63%)
Streaming Delayed Price
Updated: 1:00 PM EDT, Jul 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about BioNTech SE - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CureVac N.V. (Nasdaq - CVAC), Know Labs, Inc. (NYSE American - KNW), Volato Group, Inc. (NYSE American - SOAR), Heliogen, Inc. (OTC - HLGN)
June 13, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
June 12, 2025
From
BioNTech SE
Via
GlobeNewswire
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
June 11, 2025
EQNX::TICKER_START (NNASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NASDAQ:BNTX),(NASDAQ:ARVN),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
June 02, 2025
From
Bristol Myers Squibb
Via
Business Wire
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
June 11, 2025
From
FN Media Group LLC
Via
GlobeNewswire
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
June 02, 2025
From
BioNTech SE
Via
GlobeNewswire
BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting
May 27, 2025
From
BioNTech SE
Via
GlobeNewswire
BioNTech Announces First Quarter 2025 Financial Results and Corporate Update
May 05, 2025
From
BioNTech SE
Via
GlobeNewswire
BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer
May 05, 2025
From
BioNTech SE
Via
GlobeNewswire
BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025
April 24, 2025
From
BioNTech SE
Via
GlobeNewswire
BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025
April 22, 2025
From
BioNTech SE
Via
GlobeNewswire
BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
March 10, 2025
From
BioNTech SE
Via
GlobeNewswire
BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025
February 24, 2025
From
BioNTech SE
Via
GlobeNewswire
BioNTech Completes Acquisition of Biotheus
February 03, 2025
From
BioNTech SE
Via
GlobeNewswire
BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
January 14, 2025
From
BioNTech SE
Via
GlobeNewswire
BioNTech to Acquire Biotheus to Boost Oncology Strategy
November 13, 2024
From
BioNTech SE
Via
GlobeNewswire
BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update
November 04, 2024
From
BioNTech SE
Via
GlobeNewswire
BioNTech to Host Innovation Series R&D Day on November 14, 2024
October 31, 2024
From
BioNTech SE
Via
GlobeNewswire
BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024
October 21, 2024
From
BioNTech SE
Via
GlobeNewswire
4 Reasons Pfizer Could Be a Value Play You Can't Miss
October 07, 2024
Pfizer Inc. (NYSE: PFE) hit its peak during the COVID-19 pandemic when its vaccines developed with BioNTech SE (NASDAQ: BNTX) sent shares surging up to $61.71
Via
MarketBeat
BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day
October 01, 2024
From
BioNTech SE
Via
GlobeNewswire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
September 20, 2024
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
September 20, 2024
From
BioNTech SE
Via
GlobeNewswire
BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024
September 17, 2024
From
BioNTech SE
Via
GlobeNewswire
BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
September 05, 2024
From
BioNTech SE
Via
GlobeNewswire
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
September 04, 2024
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
September 04, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
August 22, 2024
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
August 22, 2024
From
BioNTech SE
Via
GlobeNewswire
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
August 19, 2024
Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release.
Via
MarketBeat
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.